Author:
Li Xia,Zheng Jie,Pan Wei-Li,Zheng Min,Lu Yan,Li Fu-Qiu,Ding Yang-Feng,Zhang Jian-Zhong,Li Hong-Ying,Rui Wen-Long
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Dermatology
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study;Drug Safety;2024-04-30
2. Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study;Dermatology and Therapy;2024-03-27
3. A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis;British Journal of Dermatology;2024-02-15
4. Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study;Advances in Therapy;2023-10-12
5. Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study;BioDrugs;2023-09-22